Schrodinger, Inc. SDGR

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

We are transforming the way therapeutics and materials are discovered.

Our differentiated, physics-based computational platform enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at a lower cost, compared to traditional methods. Our software platform is licensed by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. We are applying our computational platform to advance a broad pipeline of drug discovery programs in collaboration with leading biopharmaceutical companies. In addition, we use our computational platform to discover novel molecules for our pipeline of proprietary drug discovery programs, which we are advancing through preclinical and clinical development.

Last close 23.80 2026-10-23
Market cap $1.78B estimated share count
52-week range 10.95 - 33.78

Valuation FY2025 figures against the last close

P/S6.9x
P/E—
P/FCF142.7x
EV/EBITDA—
Dividend yield—
Diluted EPS-1.41

Where the revenue comes from as reported in the latest 10-K

Revenue by geography

  • United States
  • Emea
  • Apac
  • Other
Revenue by geography, 4 categories over 3 years. The same figures are in the table below. FY2025 United States, FY2025: 153M (59.8%) 60% United States Emea, FY2025: 75.2M (29.4%) 29% Emea Apac, FY2025: 26.2M (10.2%) 10% Apac Other, FY2025: 1.6M (0.6%) FY2024 United States, FY2024: 114.9M (55.3%) 55% Emea, FY2024: 65.7M (31.6%) 32% Apac, FY2024: 25.8M (12.4%) 12% Other, FY2024: 1.2M (0.6%) FY2023 United States, FY2023: 162M (74.8%) 75% Emea, FY2023: 29.1M (13.4%) 13% Apac, FY2023: 24.6M (11.3%) 11% Other, FY2023: 1M (0.5%)
Region FY2025FY2024FY2023
United States $153.0M $114.9M $162.0M
Emea $75.2M $65.7M $29.1M
Apac $26.2M $25.8M $24.6M
Other $1.6M $1.2M $1.0M

As the company reported it, from the “Segment Reporting - Schedule of Revenues by Geographic Area (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Regions are the filer's own and are not mapped onto a standard list — one company's “Americas” and another's “United States” are different areas, and making them look comparable would mean making at least one of them wrong. Slices under 1% are folded into “Other”.

Revenue by segment

  • Software
  • Drug discovery
Revenue by segment, 2 categories over 3 years. The same figures are in the table below. FY2025 Software, FY2025: 199.5M (78.0%) 78% Software Drug discovery, FY2025: 56.4M (22.0%) 22% Drug discovery FY2024 Software, FY2024: 180.4M (86.9%) 87% Drug discovery, FY2024: 27.2M (13.1%) 13% FY2023 Software, FY2023: 159.1M (73.4%) 73% Drug discovery, FY2023: 57.5M (26.6%) 27%
Segment FY2025FY2024FY2023
Software $199.5M $180.4M $159.1M
Drug discovery $56.4M $27.2M $57.5M

As the company reported it, from the “Segment Reporting - Summary of Financial Information with Respect to Reportable Segments (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Segments are the filer's own reporting structure, which is a decision about how it runs itself rather than a standard taxonomy: two companies in the same industry routinely divide themselves along different lines, so these are worth reading down a single company rather than across two. Slices under 1% are folded into “Other”.

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue $255.9M$207.5M$216.7M$181.0M$137.9M$108.1M$85.5M—
Cost of revenue $113.3M$75.5M$76.0M$79.9M$72.3M$44.6M$36.5M—
Gross profit $142.6M$132.1M$140.7M$101.0M$65.6M$63.5M$49.1M—
R&D $173.1M$201.8M$181.8M$126.4M$90.9M$64.7M$39.4M—
SG&A $95.4M$99.7M$99.1M$90.8M$64.0M$41.9M$27.0M—
Total operating expenses $309.5M$341.4M$318.1M$247.8M$177.1M$124.4M$87.8M—
Operating income -$166.9M-$209.3M-$177.4M-$146.8M-$111.4M-$60.9M-$38.7M—
Pre-tax income -$102.3M-$185.7M$42.9M-$149.1M-$100.8M-$26.3M-$26.0M—
Income tax $939.0K$1.4M$2.2M$63.0K$411.0K$345.0K$291.0K—
Net income -$103.3M-$187.1M$40.7M-$149.2M-$101.2M-$24.5M-$24.6M—
EPS, basic -1.41-2.570.57-2.10-1.42-0.41——
EPS, diluted -1.41-2.570.54-2.10-1.42-0.41-4.09—
Shares, diluted (wtd. avg.) 73.4M72.7M75.0M71.2M70.6M60.0M——

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash and equivalents $230.5M$147.3M$161.1M$95.7M$123.3M$202.8M$26.5M$77.7M
Short-term investments $164.9M$204.8M$307.7M$360.6M$456.2M$440.4M$59.8M—
Receivables $83.0M$235.7M$66.0M$56.0M$31.7M$31.4M$18.7M—
Total current assets $519.3M$635.0M$567.8M$534.0M$625.1M$683.0M$118.5M—
Property, plant and equipment ———$14.2M$10.0M$5.1M$6.3M—
Goodwill $4.8M$4.8M$4.8M$4.8M$0———
Other intangibles ——$0$587.0K$0———
Total assets $726.2M$823.2M$803.0M$688.6M$756.5M$746.3M$155.3M—
Accounts payable $11.5M$10.7M$16.8M$9.5M$8.1M$8.4M$3.5M—
Total current liabilities $189.1M$191.7M$133.7M$108.8M$91.2M$73.2M$45.0M—
Total liabilities $362.1M$401.8M$254.4M$240.7M$199.4M$122.2M$57.0M—
Retained earnings -$628.8M-$525.5M-$338.4M-$379.1M-$230.0M-$129.6M-$105.1M—
Total equity $364.1M$421.4M$548.6M$447.9M$557.1M$624.0M-$93.3M-$71.6M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Operating cash flow $13.9M-$157.4M-$136.7M-$119.7M-$70.7M$16.8M-$26.1M—
Depreciation and amortisation $6.0M$6.2M$5.6M$4.3M$2.8M$3.7M$3.6M—
Stock-based compensation $43.0M$49.9M$47.8M$39.6M$26.5M$10.5M$2.2M—
Capital expenditure $1.4M$7.3M$13.4M$8.0M$7.2M$2.5M$1.8M—
Investing cash flow $57.9M$148.8M$193.0M$90.0M-$16.8M-$381.7M-$53.9M—
Financing cash flow $2.9M$10.1M$9.0M$2.1M$8.0M$541.3M$28.7M—

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001490978-26-000026.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -200M 0 200M 400M Revenue, FY2019: 85.5M Gross profit, FY2019: 49.1M Net income, FY2019: -24.6M Revenue, FY2020: 108.1M Gross profit, FY2020: 63.5M Net income, FY2020: -24.5M Revenue, FY2021: 137.9M Gross profit, FY2021: 65.6M Net income, FY2021: -101.2M Revenue, FY2022: 181M Gross profit, FY2022: 101M Net income, FY2022: -149.2M Revenue, FY2023: 216.7M Gross profit, FY2023: 140.7M Net income, FY2023: 40.7M Revenue, FY2024: 207.5M Gross profit, FY2024: 132.1M Net income, FY2024: -187.1M Revenue, FY2025: 255.9M Gross profit, FY2025: 142.6M Net income, FY2025: -103.3M FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue — $85.5M $108.1M $137.9M $181.0M $216.7M $207.5M $255.9M
Gross profit — $49.1M $63.5M $65.6M $101.0M $140.7M $132.1M $142.6M
Net income — -$24.6M -$24.5M -$101.2M -$149.2M $40.7M -$187.1M -$103.3M

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Officer or director change Item 5.02
  • Officer or director change Item 5.02
  • Regulation FD disclosure Item 7.01
  • Results announced Item 2.02
  • Officer or director change Item 5.02
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Results announced Item 2.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%